Skip to main content
  • Prescribing information
  • Contact Us
  • Bayer Global
  • Canada
  • Philippines
  • South Africa
  • Switzerland
  • UK
  • US
Alt Betaferon
  • About MS

    Header

    Caption

    • Types of MS
    • Diagnosing MS
    • The pathological substrate of MS
    • Treatments and therapies
  • BETAFERON
    • Mode of action of BETAFERON
    • Main clinical studies of Betaferon
      • BENEFIT
      • Pivotal study
      • SPMS studies
    • BETAFERON long-term data
      • Long-term data from studies in early MS
        • Time to CDMS
        • Disability
        • Cognitive test: PASAT
        • Employment
        • Quality of life
      • Long-term data from studies in established RRMS
        • Outcomes of the 16-Year LTF
        • Vital status at 21-Year LTF
      • Long-term data on interferon beta from observational MS patient cohorts
    • BETAFERON clinical experience and safety
      • Strategies to improve tolerability of BETAFERON
  • BETAPLUS
    • Autoinjectors available for BETAFERON
      • BETACONNECT
      • BETAJECT COMFORT
  • Pregnancy
    • Pregnancy rates are rising among women with MS
    • Patterns of MS activity before, during and after pregnancy
    • Genetic risk
    • Time to conceive
      • Assisted reproductive treatment (ART)
    • Unplanned pregnancies
    • Betaferon and pregnancy – Excerpt from the European SmPC
    • Betaferon / IFNB pregnancy registry data
      • Interferon beta-1b specific data
      • The European interferon beta Pregnancy Registry
      • The Register-based cohort study in Finland and Sweden
    • Breastfeeding
    • Informed patients
    • MS and pregnancy –viewpoints of MS experts from around the world
  • Middle life years
    • The MS population is ageing
      • Late onset MS
      • The patient’s view
    • Insights into ageing processes
      • Immunosenescence
        • MS and infections
        • MS and immunization
        • Telomere shortening
      • Co-morbidities
        • Polypharmacy
      • Lifestyle factors
        • Physical exercise
        • Diet
        • Smoking
    • Disease course of MS patients when they age
      • Transition between RRMS and SPMS
    • Betaferon in mid-life or older patients with MS
      • Mode of action
      • Clinical data
        • Data from an observational study
      • Treatment continuation?
      • De-escalation experience
    • Treatment of mid-life or older patients with MS – safety considerations
    • MS and ageing – viewpoints of MS experts from around the world
  • MS Academy

    MS Academy

  • About MS
    • Types of MS
    • Diagnosing MS
    • The pathological substrate of MS
    • Treatments and therapies
  • BETAFERON
    • Mode of action of BETAFERON
    • Main clinical studies of Betaferon
      • BENEFIT
      • Pivotal study
      • SPMS studies
    • BETAFERON long-term data
      • Long-term data from studies in early MS
        • Time to CDMS
        • Disability
        • Cognitive test: PASAT
        • Employment
        • Quality of life
      • Long-term data from studies in established RRMS
        • Outcomes of the 16-Year LTF
        • Vital status at 21-Year LTF
      • Long-term data on interferon beta from observational MS patient cohorts
    • BETAFERON clinical experience and safety
      • Strategies to improve tolerability of BETAFERON
  • BETAPLUS
    • Autoinjectors available for BETAFERON
      • BETACONNECT
      • BETAJECT COMFORT
  • Pregnancy
    • Pregnancy rates are rising among women with MS
    • Patterns of MS activity before, during and after pregnancy
    • Genetic risk
    • Time to conceive
      • Assisted reproductive treatment (ART)
    • Unplanned pregnancies
    • Betaferon and pregnancy – Excerpt from the European SmPC
    • Betaferon / IFNB pregnancy registry data
      • Interferon beta-1b specific data
      • The European interferon beta Pregnancy Registry
      • The Register-based cohort study in Finland and Sweden
    • Breastfeeding
    • Informed patients
    • MS and pregnancy –viewpoints of MS experts from around the world
  • Middle life years
    • The MS population is ageing
      • Late onset MS
      • The patient’s view
    • Insights into ageing processes
      • Immunosenescence
        • MS and infections
        • MS and immunization
        • Telomere shortening
      • Co-morbidities
        • Polypharmacy
      • Lifestyle factors
        • Physical exercise
        • Diet
        • Smoking
    • Disease course of MS patients when they age
      • Transition between RRMS and SPMS
    • Betaferon in mid-life or older patients with MS
      • Mode of action
      • Clinical data
        • Data from an observational study
      • Treatment continuation?
      • De-escalation experience
    • Treatment of mid-life or older patients with MS – safety considerations
    • MS and ageing – viewpoints of MS experts from around the world
  • MS Academy
  • Country select
    • Canada
    • Philippines
    • South Africa
    • Switzerland
    • UK
    • US
  • Prescribing information
  • Contact Us
  • Bayer Global
Breadcrumb
  1. Home
  2. Middle life years
  3. Betaferon in mid-life or older patients with MS

BETAFERON in mid-life or older patients with MS


 

 

Aspects to consider

 

Mode of action of BETAFERON in MS

Read more

Clinical data

Read more

Should treatment be continued when MS patients get older and disease is less active?

Read more

De-escalation of therapy

Read more

Treatment of mid-life or older patients with MS – safety considerations

Read more

 

Return to 'middle life years'

 

Alt tag
  • Privacy Statement
  • Conditions of use
  • Imprint
  • Bayer.com Portal
  • Report a side effect
  • Sitemap

© 2022 Bayer AG

This website contains information on BETAFERON (interferon beta-1b) which is based on the Summary of Product Characteristics (SmPC) as approved by the European Commission. It is intended to provide information to an international audience outside of Austria, Canada, South Africa, Switzerland, the USA and UK

Approval code

  • PP-BET-ALL-0212-1

Last updated on 14/01/2022

hidden link for autofocus
Cookie consent image